ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Food-Derived Biohybrid Probiotic Extracellular Vesicles for Synergistic Therapy of Inflammatory Bowel Disease.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiome signatures and mechanistic pathways in pediatric obesity: from early-life risk to precision interventions.World journal of pediatrics : WJP · 2026Review
- Extracellular vesicle-based therapies in IBD: immunomodulation, regeneration, and translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Inflammatory bowel disease is a chronic gastrointestinal disorder characterized by persistent intestinal inflammation, microbiota dysbiosis, and impaired mucosal barrier function. Conventional treatments, including pharmacological agents, biologics, and fecal microbiota transplantation, are limited by adverse effects, immune suppression, recurrence, and low patient acceptance. In this study, food-derived probiotic extracellular vesicles (EVs) from Lactiplantibacillus plantarum with dietary polysaccharide (chitosan) and polyphenol (tannic acid) are developed as a synergistic therapeutic strategy for inflammatory bowel disease. The engineered biohybrid with dual-functional coating confers gastrointestinal stability and colon-targeted delivery, while scavenging reactive oxygen species and preserving the intrinsic microbiota-regulating properties of probiotic EVs. Multi-omics approach reveals correlations among microbial community shifts, short-chain fatty acids, oxidative stress modulation, inflammatory cytokine profiles, and disease severity indices. This work provides a promising approach and reveals the synergistic mechanisms of engineered probiotic EVs in reshaping gut microbiota, modulating metabolic networks, and improving the inflammatory microenvironment for the treatment of inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.